Leonard Price was ninety-two when his attorney contacted Sophie.
She almost deleted the message.
NorthStar's former chief executive had spent years in federal prison before age and illness moved him into supervised medical custody.
His name appeared on authorizations.
Payments.
Facility contracts.
Monitoring programs.
Unlike Samuel, Price had never claimed scientific obsession.
He claimed ignorance.
Delegation.
Corporate distance.
Juries had rejected much of it.
Sophie had not thought about him in years.
The attorney's request was simple.
Mr. Price wished to speak with her once.
No media.
No recording unless Sophie wanted it.
No request for forgiveness.
Sophie declined.
Three weeks later the attorney wrote again.
Price had documents he believed belonged to her.
Sophie forwarded the message to Bell.
Bell was retired now.
He still answered.
“Let attorneys handle the documents.”
“Do I need to meet him?”
“No.”
“Do you think I should?”
Bell paused.
“That's not my decision.”
Sophie smiled.
Everyone had learned.
The documents were transferred to the public trust.
Most duplicated known material.
One did not.
A private NorthStar valuation memo.
PROJECT RESURRECTION — COMMERCIAL POTENTIAL.
Sophie read the first page.
Then wished she had not.
The program projected enormous revenue from preventive gene therapy for hereditary cancer.
Not treatment after disease.
Intervention before symptoms.
A market measured in millions of high-risk children and adults worldwide.
The Hale-Mercer case appeared as proof-of-concept potential.
Sophie had been ten when NorthStar classified her biology as commercially viable.
Earlier internal documents valued successful control of her receptor system at billions.
She stared.
There it was.
Money.
Not the only motive.
Samuel wanted control over disease.
Vale wanted scientific achievement.
Cross wanted biological data.
Vane protected the system.
But NorthStar's executives saw something simpler.
A product.
Sophie called Price's attorney.
“I'll meet him.”
The meeting took place in a medical facility.
Price was thin.
Oxygen.
Wheelchair.
Sharp eyes.
Sophie sat opposite him.
No Claire now.
No Daniel.
No Eric.
She had come alone.
Price studied her.
“You look like your mother.”
Sophie disliked him immediately.
“Don't.”
He nodded.
“Understood.”
She placed the valuation memo on the table.
“Explain.”
Price looked at it.
“You understand it.”
“I want to hear you say it.”
He breathed through the oxygen cannula.
“We believed a preventive therapy could be worth billions.”
“We?”
“NorthStar.”
“Children.”
“Patients with hereditary risk.”
“Children.”
“Yes.”
Sophie waited.
Price looked down.
“We believed parents would pay almost anything to prevent cancer.”
That sentence explained more than any scientific document.
Fear as market.
Parental love as leverage.
Risk transformed into demand.
Sophie asked, “Did you know Samuel had treated me without consent?”
“At first, no.”
“Later?”
“Yes.”
“When?”
“Before the school activator.”
Sophie felt cold.
“So you knew.”
“Yes.”
“And continued.”
“Yes.”
“Why?”
Price did not hide behind legal language.
“Because by then too much money had been spent.”
Sunk cost.
Sophie almost laughed.
The phrase had haunted everything.
“How much?”
“Hundreds of millions across related programs.”
“And that made one child expendable?”
Price looked at her.
“No.”
“But you acted like it.”
“Yes.”
“Why the activator?”
“To produce measurable proof.”
There it was.
NorthStar needed the dormant vector to demonstrate an effect.
Without activation, Sophie's childhood intervention might remain scientifically ambiguous for years.
Investors were losing patience.
Vale proposed triggering the system under cover of routine school immunization.
Price approved funding.
“You knew it could cause tumors?”
“We knew there was risk.”
“How much?”
“Unknown.”
Sophie leaned forward.
“You gave an unknown-risk activator to children because investors wanted data.”
Price closed his eyes.
“Yes.”
“Five children.”
“Yes.”
“Why them?”
“Biological markers suggested responsiveness.”
“Joshua Reed.”
“Yes.”
“The others.”
“Yes.”
“Sophie Morgan.”
Price looked at her.
“Yes.”
Hearing her own name mattered.
Not S.H.-10.
Not subject.
Not viable.
Sophie Morgan.
She asked, “Did Samuel approve?”
“No.”
That aligned with the evidence.
Samuel created the system.
NorthStar weaponized it commercially beyond even his intended design.
That did not absolve him.
It clarified the chain.
“Why did you keep Samuel involved?”
“He understood the platform.”
“Why did he stay?”
“He believed he could limit what we did.”
Sophie almost laughed.
“He thought he could control you.”
“Yes.”
“And you thought you could control him.”
“Yes.”
“How did that work?”
Price smiled faintly.
“Poorly.”
Sophie did not smile.
Price coughed.
A nurse entered.
He waved her away.
Sophie noticed.
The nurse stopped.
“Mr. Price, I need to check—”
“No.”
The nurse looked at him.
Then Sophie.
Then back.
“Okay. I'll return in ten minutes.”
She left.
Sophie stared at Price.
“You said no.”
“Yes.”
“And she stopped.”
Price understood.
His face changed.
“I see.”
“Do you?”
“Yes.”
Sophie doubted it.
Still, the moment sat between them.
Price asked whether she wanted to know why he requested the meeting.
“I assumed guilt.”
“Partly.”
“What else?”
“My granddaughter.”
Sophie stiffened.
“She has a hereditary cancer mutation.”
Of course.
Life had no sense of subtlety.
“She is six.”
Price continued.
“My son wants every possible test.”
“And?”
“My granddaughter's mother does not.”
“Why are you telling me?”
“Because they asked what I thought.”
Sophie stared.
“And you couldn't answer.”
“No.”
“Why ask me?”
“Because you know what happens when fear becomes permission.”
Sophie felt anger.
“You want me to make your family decision?”
“No.”
“Then what?”
Price swallowed.
“I want to know what I should tell them.”
Sophie almost stood.
Then stayed.
“Tell them what you did.”
He looked confused.
“All of it?”
“Yes.”
“She is six.”
“Tell her parents.”
“What about her?”
“Age-appropriate truth.”
Price nodded slowly.
Sophie continued.
“And tell them uncertainty doesn't mean do nothing. It means find doctors who explain what testing can actually change.”
Price listened.
“If there's a proven surveillance plan, use it.”
“Yes.”
“If there isn't?”
“Then they decide how much they want to know.”
“And the child?”
“Gets more say as she becomes able to understand.”
Price looked toward the window.
“I wish someone had said that thirty years ago.”
Sophie shook her head.
“They did.”
He looked back.
“Who?”
“People said versions of it constantly.”
Elaine.
Thomas.
Ethics boards.
Parents.
Eventually Dr. Shah.
The problem had not been absence of warnings.
It had been powerful people deciding warnings came from cowards.
Price nodded.
“You're right.”
Sophie stood.
He looked alarmed.
“That's it?”
“Yes.”
“Do you forgive me?”
The question irritated her more than she expected.
“No.”
Price lowered his head.
Sophie continued.
“But that wasn't why I came.”
“Why did you?”
She looked at the valuation memo.
“I wanted the last missing motive in plain language.”
“Money.”
“Yes.”
He nodded.
“Money.”
Sophie left.
Price died six weeks later.
His granddaughter's family eventually chose established hereditary surveillance.
No experimental intervention.
No broad predictive panels beyond clinically relevant genes.
The child was told gradually as she grew.
Sophie knew only because Price's son sent one letter years later.
No medical details.
Just thanks.
She filed it with the trust.
Not her personal archive.
At sixty, Sophie retired from full-time architecture.
She had designed or renovated eleven pediatric hospitals and dozens of clinics.
Nora became a teacher.
Not a doctor.
Not a geneticist.
Sophie loved that.
The Hale-Mercer mutations continued through the family in uneven ways.
Some relatives carried one.
Some neither.
No one treated inheritance as prophecy anymore.
Surveillance when useful.
Testing when chosen.
Treatment when evidence supported it.
Questions when uncertain.
One afternoon Sophie visited the public trust.
The director showed her the archive.
Rows of boxes.
Digitized records.
Restricted files.
Samuel's work.
NorthStar evidence.
Ethics reviews.
Patient testimony.
Her own case somewhere inside.
Sophie asked, “How often do people request my file?”
“Rarely.”
“Good.”
“Researchers mostly request the ethics material now.”
“Better.”
The director showed her one exhibit used for medical training.
No names.
No photographs.
A single timeline demonstrating how a legitimate goal—prevent hereditary cancer—had crossed boundary after boundary until children became experimental infrastructure.
At the end was a question.
At what point should the project have stopped?
Sophie read it.
Then laughed softly.
“What?”
The director looked concerned.
“Nothing.”
Sophie pointed.
“People always want one point.”
“There were many.”
“Yes.”
The first unauthorized test.
The forged consent.
Maya.
The infant vector.
The hidden monitoring.
The school activator.
The delayed treatment.
Every stage offered another chance to stop.
That was more frightening than a single villainous decision.
Also more useful.
Systems failed repeatedly.
Which meant systems could be designed to interrupt failure repeatedly too.
Independent review.
Transparent consent.
Assent.
Withdrawal.
Data limits.
Whistleblower protection.
Patient advocates.
No single brilliant person controlling everything.
The safeguards sounded boring.
Sophie loved boring.
Before leaving, the director asked whether she wanted to see her original S.H.-10 notebook.
Samuel's handwritten one.
Sophie thought.
“No.”
“You've never requested it.”
“I know.”
“You're sure?”
“Yes.”
The director closed the archive drawer.
No disappointment.
No persuasion.
Sophie smiled.
Decades had passed.
People had died.
Institutions changed.
Scientific language evolved.
Her body aged.
The scar near her ovary softened.
The pineal lesion became an incidental line in old imaging history.
But one thing still measured the distance traveled better than anything else.
She could stand in front of a box containing answers about herself.
Say no.
And watch someone close it.
Click here to continue reading: PART 41: Sophie Thought the Archive Had Finally Become History, Until Nora Asked Whether the Family’s Genetic Risk Should Be Tested Before She Became a Mother
The Nurse Stopped Smiling Before She Closed the Door, and Claire Knew Sophie’s Routine Blood Test Had Found Something Wrong
Part 40 of 47
